Spinocerebellar ataxia type 3 (SCA3), or Machado-Joseph disease (MJD), is a progressive neurodegenerative disorder caused by a CAG expansion in the ATXN3 gene. The expanded CAG repeat is translated into a prolonged polyglutamine repeat in the ataxin-3 protein and accumulates within inclusions, acquiring toxic properties, which results in degeneration of the cerebellum and brain stem. In the current study, a non-allele-specific ATXN3 silencing approach was investigated using artificial microRNAs engineered to target various regions of the ATXN3 gene (miATXN3). The miATXN3 candidates were screened in vitro based on their silencing efficacy on a luciferase (Luc) reporter co-expressing ATXN3. The three best miATXN3 candidates were further tested for target engagement and potential off-target activity in induced pluripotent stem cells (iPSCs) differentiated into frontal brain-like neurons and in a SCA3 knockin mouse model. Besides a strong reduction of ATXN3 mRNA and protein, small RNA sequencing revealed efficient guide strand processing without passenger strands being produced. We used different methods to predict alteration of off-target genes upon AAV5-miATXN3 treatment and found no evidence for unwanted effects. Furthermore, we demonstrated in a large animal model, the minipig, that intrathecal delivery of AAV5 can transduce the main areas affected in SCA3 patients. These results proved a strong basis to move forward to investigate distribution, efficacy, and safety of AAV5-miATXN3 in large animals.

Department of Gastroenterology and Hepatology Leiden University Medical Center Leiden the Netherlands

Department of Human Genetics Medical Faculty Ruhr University Bochum Bochum Germany

Department of Research and Development uniQure Biopharma B 5 Amsterdam the Netherlands

Institute of Animal Physiology and Genetics Libechov Czech Republic

Institute of Medical Genetics and Applied Genomics University of Tuebingen Tuebingen Germany

Zobrazit více v PubMed

Matos C., de Almeida L.P., Nóbrega C. Machado-Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy. J. Neurochem. 2019;148:8–28. PubMed

Coutinho P., Andrade C. Autosomal dominant system degeneration in Portuguese families of the Azores Islands. A new genetic disorder involving cerebellar, pyramidal, extrapyramidal and spinal cord motor functions. Neurology. 1978;28:703–709. PubMed

Rosenberg R.N. Machado-Joseph disease: an autosomal dominant motor system degeneration. Mov. Disord. 1992;7:193–203. PubMed

Ranum L.P., Lundgren J.K., Schut L.J., Ahrens M.J., Perlman S., Aita J., Bird T.D., Gomez C., Orr H.T. Spinocerebellar ataxia type 1 and Machado-Joseph disease: incidence of CAG expansions among adult-onset ataxia patients from 311 families with dominant, recessive, or sporadic ataxia. Am. J. Hum. Genet. 1995;57:603–608. PubMed PMC

Schöls L., Bauer P., Schmidt T., Schulte T., Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol. 2004;3:291–304. PubMed

Kawaguchi Y., Okamoto T., Taniwaki M., Aizawa M., Inoue M., Katayama S., Kawakami H., Nakamura S., Nishimura M., Akiguchi I. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat. Genet. 1994;8:221–228. PubMed

Maciel P., Costa M.C., Ferro A., Rousseau M., Santos C.S., Gaspar C., Barros J., Rouleau G.A., Coutinho P., Sequeiros J. Improvement in the molecular diagnosis of Machado-Joseph disease. Arch. Neurol. 2001;58:1821–1827. PubMed

Cummings C.J., Zoghbi H.Y. Trinucleotide repeats: mechanisms and pathophysiology. Annu. Rev. Genomics Hum. Genet. 2000;1:281–328. PubMed

Maciel P., Gaspar C., DeStefano A.L., Silveira I., Coutinho P., Radvany J., Dawson D.M., Sudarsky L., Guimarães J., Loureiro J.E. Correlation between CAG repeat length and clinical features in Machado-Joseph disease. Am. J. Hum. Genet. 1995;57:54–61. PubMed PMC

Bettencourt C., Lima M. Machado-Joseph disease: from first descriptions to new perspectives. Orphanet J. Rare Dis. 2011;6:35. PubMed PMC

Goto J., Watanabe M., Ichikawa Y., Yee S.B., Ihara N., Endo K., Igarashi S., Takiyama Y., Gaspar C., Maciel P. Machado-Joseph disease gene products carrying different carboxyl termini. Neurosci. Res. 1997;28:373–377. PubMed

Ichikawa Y., Goto J., Hattori M., Toyoda A., Ishii K., Jeong S.Y., Hashida H., Masuda N., Ogata K., Kasai F. The genomic structure and expression of MJD, the Machado-Joseph disease gene. J. Hum. Genet. 2001;46:413–422. PubMed

Paulson H.L., Perez M.K., Trottier Y., Trojanowski J.Q., Subramony S.H., Das S.S., Vig P., Mandel J.L., Fischbeck K.H., Pittman R.N. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron. 1997;19:333–344. PubMed

Macedo-Ribeiro S., Cortes L., Maciel P., Carvalho A.L. Nucleocytoplasmic shuttling activity of ataxin-3. PLoS ONE. 2009;4:e5834. PubMed PMC

Schmidt T., Landwehrmeyer G.B., Schmitt I., Trottier Y., Auburger G., Laccone F., Klockgether T., Völpel M., Epplen J.T., Schöls L., Riess O. An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathol. 1998;8:669–679. PubMed PMC

Trottier Y., Cancel G., An-Gourfinkel I., Lutz Y., Weber C., Brice A., Hirsch E., Mandel J.L. Heterogeneous intracellular localization and expression of ataxin-3. Neurobiol. Dis. 1998;5:335–347. PubMed

Riess O., Rüb U., Pastore A., Bauer P., Schöls L. SCA3: neurological features, pathogenesis and animal models. Cerebellum. 2008;7:125–137. PubMed

Evers M.M., Toonen L.J.A., van Roon-Mom W.M.C. Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies. Mol. Neurobiol. 2014;49:1513–1531. PubMed PMC

Wang L.C., Chen K.Y., Pan H., Wu C.C., Chen P.H., Liao Y.T., Li C., Huang M.L., Hsiao K.M. Muscleblind participates in RNA toxicity of expanded CAG and CUG repeats in Caenorhabditis elegans. Cell. Mol. Life Sci. 2011;68:1255–1267. PubMed PMC

Miller J.W., Urbinati C.R., Teng-Umnuay P., Stenberg M.G., Byrne B.J., Thornton C.A., Swanson M.S. Recruitment of human muscleblind proteins to (CUG)n expansions associated with myotonic dystrophy. EMBO J. 2000;19:4439–4448. PubMed PMC

Fardaei M., Larkin K., Brook J.D., Hamshere M.G. In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts. Nucleic Acids Res. 2001;29:2766–2771. PubMed PMC

Jiang H., Mankodi A., Swanson M.S., Moxley R.T., Thornton C.A. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum. Mol. Genet. 2004;13:3079–3088. PubMed

Eichler L., Bellenberg B., Hahn H.K., Köster O., Schöls L., Lukas C. Quantitative assessment of brain stem and cerebellar atrophy in spinocerebellar ataxia types 3 and 6: impact on clinical status. AJNR Am. J. Neuroradiol. 2011;32:890–897. PubMed PMC

Sudarsky L., Corwin L., Dawson D.M. Machado-Joseph disease in New England: clinical description and distinction from the olivopontocerebellar atrophies. Mov. Disord. 1992;7:204–208. PubMed

Sequeiros J., Coutinho P. Epidemiology and clinical aspects of Machado-Joseph disease. Adv. Neurol. 1993;61:139–153. PubMed

Nóbrega C., Nascimento-Ferreira I., Onofre I., Albuquerque D., Hirai H., Déglon N., de Almeida L.P. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice. PLoS ONE. 2013;8:e52396. PubMed PMC

Alves S., Nascimento-Ferreira I., Dufour N., Hassig R., Auregan G., Nóbrega C., Brouillet E., Hantraye P., Pedroso de Lima M.C., Déglon N., de Almeida L.P. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3? Hum. Mol. Genet. 2010;19:2380–2394. PubMed

Rodríguez-Lebrón E., Costa Mdo.C., Luna-Cancalon K., Peron T.M., Fischer S., Boudreau R.L., Davidson B.L., Paulson H.L. Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice. Mol. Ther. 2013;21:1909–1918. PubMed PMC

Evers M.M., Miniarikova J., Juhas S., Vallès A., Bohuslavova B., Juhasova J., Skalnikova H.K., Vodicka P., Valekova I., Brouwers C. AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a Huntington’s Disease minipig model. Mol. Ther. 2018;26:2163–2177. PubMed PMC

Miniarikova J., Zanella I., Huseinovic A., van der Zon T., Hanemaaijer E., Martier R., Koornneef A., Southwell A.L., Hayden M.R., van Deventer S.J. Design, characterization, and lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for Huntington’s disease. Mol. Ther. Nucleic Acids. 2016;5:e297. PubMed PMC

Miniarikova J., Evers M.M., Konstantinova P. Translation of microRNA-based huntingtin-lowering therapies from preclinical studies to the clinic. Mol. Ther. 2018;26:947–962. PubMed PMC

Herrera-Carrillo E., Berkhout B. Dicer-independent processing of small RNA duplexes: mechanistic insights and applications. Nucleic Acids Res. 2017;45:10369–10379. PubMed PMC

Keskin S., Brouwers C.C., Sogorb-Gonzalez M., Martier R., Depla J.A., Vallès A., van Deventer S.J., Konstantinova P., Evers M.M. AAV5-miHTT lowers huntingtin mRNA and protein without off-target effects in patient-derived neuronal cultures and astrocytes. Mol. Ther. Methods Clin. Dev. 2019;15:275–284. PubMed PMC

Klein R.L., Hamby M.E., Gong Y., Hirko A.C., Wang S., Hughes J.A., King M.A., Meyer E.M. Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain. Exp. Neurol. 2002;176:66–74. PubMed

Martier R., Liefhebber J.M., García-Osta A., Miniarikova J., Cuadrado-Tejedor M., Espelosin M., Ursua S., Petry H., van Deventer S.J., Evers M.M., Konstantinova P. Targeting RNA-mediated toxicity in C9orf72 ALS and/or FTD by RNAi-based gene therapy. Mol. Ther. Nucleic Acids. 2019;16:26–37. PubMed PMC

Yang J.-S., Maurin T., Robine N., Rasmussen K.D., Jeffrey K.L., Chandwani R., Papapetrou E.P., Sadelain M., O’Carroll D., Lai E.C. Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis. Proc. Natl. Acad. Sci. USA. 2010;107:15163–15168. PubMed PMC

Cifuentes D., Xue H., Taylor D.W., Patnode. H., Mishima. Y., Cheloufi S., Ma E., Mane S., Hannon G.J., Lawson N.D. A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science. 2010;328:1694–1698. PubMed PMC

Cheloufi S., Dos Santos C.O., Chong M.M.W., Hannon G.J. A Dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature. 2010;465:584–589. PubMed PMC

Yoda M., Cifuentes D., Izumi N., Sakaguchi Y., Suzuki T., Giraldez A.J., Tomari Y. Poly(A)-specific ribonuclease mediates 3′-end trimming of Argonaute2-cleaved precursor microRNAs. Cell Rep. 2013;5:715–726. PubMed PMC

Bezprozvanny I., Klockgether T. Therapeutic prospects for spinocerebellar ataxia type 2 and 3. Drugs Future. 2009;34:991–999. PubMed PMC

Nguyen H.P., Hübener J., Weber J.J., Grueninger S., Riess O., Weiss A. Cerebellar soluble mutant ataxin-3 level decreases during disease progression in spinocerebellar ataxia type 3 mice. PLoS ONE. 2013;8:e62043. PubMed PMC

Plass M., Rasmussen S.H., Krogh A. Highly accessible AU-rich regions in 3′ untranslated regions are hotspots for binding of regulatory factors. PLoS Comput. Biol. 2017;13:e1005460. PubMed PMC

Boudreau R.L., Spengler R.M., Hylock R.H., Kusenda B.J., Davis H.A., Eichmann D.A., Davidson B.L. siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse. Nucleic Acids Res. 2013;41:e9. PubMed PMC

Schmitt I., Linden M., Khazneh H., Evert B.O., Breuer P., Klockgether T., Wuellner U. Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination. Biochem. Biophys. Res. Commun. 2007;362:734–739. PubMed

Alves S., Nascimento-Ferreira I., Auregan G., Hassig R., Dufour N., Brouillet E., Pedroso de Lima M.C., Hantraye P., Pereira de Almeida L., Déglon N. Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS ONE. 2008;3:e3341. PubMed PMC

Evers M.M., Pepers B.A., van Deutekom J.C.T., Mulders S.A.M., den Dunnen J.T., Aartsma-Rus A., van Ommen G.J., van Roon-Mom W.M. Targeting several CAG expansion diseases by a single antisense oligonucleotide. PLoS ONE. 2011;6:e24308. PubMed PMC

Hu J., Matsui M., Gagnon K.T., Schwartz J.C., Gabillet S., Arar K., Wu J., Bezprozvanny I., Corey D.R. Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat. Biotechnol. 2009;27:478–484. PubMed PMC

Liu J., Yu D., Aiba Y., Pendergraff H., Swayze E.E., Lima W.F., Hu J., Prakash T.P., Corey D.R. ss-siRNAs allele selectively inhibit ataxin-3 expression: multiple mechanisms for an alternative gene silencing strategy. Nucleic Acids Res. 2013;41:9570–9583. PubMed PMC

Datson N.A., González-Barriga A., Kourkouta E., Weij R., van de Giessen J., Mulders S., Kontkanen O., Heikkinen T., Lehtimäki K., van Deutekom J.C. The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain. PLoS ONE. 2017;12:e0171127. PubMed PMC

Martier R., Liefhebber J.M., Miniarikova J., van der Zon T., Snapper J., Kolder I., Petry H., van Deventer S.J., Evers M.M., Konstantinova P. Artificial microRNAs targeting C9orf72 can reduce accumulation of intra-nuclear transcripts in ALS and FTD patients. Mol. Ther. Nucleic Acids. 2019;14:593–608. PubMed PMC

Colella P., Ronzitti G., Mingozzi F. Emerging Issues in AAV-mediated in vivo gene therapy. Mol. Ther. Methods Clin. Dev. 2017;8:87–104. PubMed PMC

Saraiva J., Nobre R.J., Pereira de Almeida L. Gene therapy for the CNS using AAVs: the impact of systemic delivery by AAV9. J. Control. Release. 2016;241:94–109. PubMed

Hocquemiller M., Giersch L., Audrain M., Parker S., Cartier N. Adeno-associated virus-based gene therapy for CNS diseases. Hum. Gene Ther. 2016;27:478–496. PubMed PMC

Zincarelli C., Soltys S., Rengo G., Rabinowitz J.E. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 2008;16:1073–1080. PubMed

Foust K.D., Nurre E., Montgomery C.L., Hernandez A., Chan C.M., Kaspar B.K. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 2009;27:59–65. PubMed PMC

Mendell J.R., Al-Zaidy S., Shell R., Arnold W.D., Rodino-Klapac L.R., Prior T.W., Lowes L., Alfano L., Berry K., Church K. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 2017;377:1713–1722. PubMed

Samaranch L., Blits B., San Sebastian W., Hadaczek P., Bringas J., Sudhakar V., Macayan M., Pivirotto P.J., Petry H., Bankiewicz K.S. MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain. Gene Ther. 2017;24:253–261. PubMed PMC

Toonen L.J.A., Rigo F., van Attikum H., van Roon-Mom W.M.C. Antisense oligonucleotide-mediated removal of the polyglutamine repeat in spinocerebellar ataxia type 3 mice. Mol. Ther. Nucleic Acids. 2017;8:232–242. PubMed PMC

Costa Mdo.C., Luna-Cancalon K., Fischer S., Ashraf N.S., Ouyang M., Dharia R.M., Martin-Fishman L., Yang Y., Shakkottai V.G., Davidson B.L. Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease. Mol. Ther. 2013;21:1898–1908. PubMed PMC

Dean B., Gibbons A., Gogos A., Udawela M., Thomas E., Scarr E. Studies on prostaglandin-endoperoxide synthase 1: lower levels in schizophrenia and after treatment with antipsychotic drugs in conjunction with aspirin. Int. J. Neuropsychopharmacol. 2018;21:216–225. PubMed PMC

Zhou F., Leder P., Martin S.S. Formin-1 protein associates with microtubules through a peptide domain encoded by exon-2. Exp. Cell Res. 2006;312:1119–1126. PubMed

Akpınar M., Lesche M., Fanourgakis G., Fu J., Anastassiadis K., Dahl A., Jessberger R. TDRD6 mediates early steps of spliceosome maturation in primary spermatocytes. PLoS Genet. 2017;13:e1006660. PubMed PMC

Wang T.H., Hsia S.M., Shieh T.M. Lysyl oxidase and the tumor microenvironment. Int. J. Mol. Sci. 2016;18:E62. PubMed PMC

Erler J.T., Bennewith K.L., Nicolau M., Dornhöfer N., Kong C., Le Q.T., Chi J.T., Jeffrey S.S., Giaccia A.J. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006;440:1222–1226. PubMed

Cox T.R., Gartland A., Erler J.T. Lysyl oxidase, a targetable secreted molecule involved in cancer metastasis. Cancer Res. 2016;76:188–192. PubMed

Kaneda A., Wakazono K., Tsukamoto T., Watanabe N., Yagi Y., Tatematsu M., Kaminishi M., Sugimura T., Ushijima T. Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers. Cancer Res. 2004;64:6410–6415. PubMed

Ozdener G.B., Bais M.V., Trackman P.C. Determination of cell uptake pathways for tumor inhibitor lysyl oxidase propeptide. Mol. Oncol. 2016;10:1–23. PubMed PMC

Scherzed W., Brunt E.R., Heinsen H., de Vos R.A., Seidel K., Bürk K., Schöls L., Auburger G., Del Turco D., Deller T. Pathoanatomy of cerebellar degeneration in spinocerebellar ataxia type 2 (SCA2) and type 3 (SCA3) Cerebellum. 2012;11:749–760. PubMed

Sudarsky L., Coutinho P. Machado-Joseph disease. Clin. Neurosci. 1995;3:17–22. PubMed

Dürr A., Stevanin G., Cancel G., Duyckaerts C., Abbas N., Didierjean O., Chneiweiss H., Benomar A., Lyon-Caen O., Julien J. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann. Neurol. 1996;39:490–499. PubMed

Yamada M., Sato T., Tsuji S., Takahashi H. CAG repeat disorder models and human neuropathology: similarities and differences. Acta Neuropathol. 2008;115:71–86. PubMed

Muñoz E., Rey M.J., Milà M., Cardozo A., Ribalta T., Tolosa E., Ferrer I. Intranuclear inclusions, neuronal loss and CAG mosaicism in two patients with Machado-Joseph disease. J. Neurol. Sci. 2002;200:19–25. PubMed

Rüb U., Brunt E.R., Deller T. New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado-Joseph disease) Curr. Opin. Neurol. 2008;21:111–116. PubMed

Paulson H.L., Das S.S., Crino P.B., Perez M.K., Patel S.C., Gotsdiner D., Fischbeck K.H., Pittman R.N. Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. Ann. Neurol. 1997;41:453–462. PubMed